Dysregulation of TGF Beta Action Pancreatic Cancer

$441,940R01FY2014CANIH

Indiana University Indianapolis, Indianapolis IN

Investigators

Linked publications & trials

Paper 37099035 Paper 35016920 Paper 31090659 Paper 30293901 Paper 30190481 Paper 30118843 Paper 29702529 Paper 29353105 Paper 29349096 Paper 28919082 Paper 28591716 Paper 28542740 Paper 28232049 Paper 28174710 Paper 28093284 Paper 27626694 Paper 27535970 Paper 27456015 Paper 27454293 Paper 27267807 Paper 27137483 Paper 26723874 Paper 26688098 Paper 26586478 Paper 26469962 Paper 26444644 Paper 26095125 Paper 25762644 Paper 25645860 Paper 25473891 Paper 25406955 Paper 25379951 Paper 25350767 Paper 25176061 Paper 25150790 Paper 25135483 Paper 24937454 Paper 24412093 Paper 24409315 Paper 24334458 Paper 24282275 Paper 24152948 Paper 24096486 Paper 24077287 Paper 23941833 Paper 22965423 Paper 22945649 Paper 22869556 Paper 22806240 Paper 22761868 Paper 22440254 Paper 22307839 Paper 22213426 Paper 22053213 Paper 21996748 Paper 21699781 Paper 21673986 Paper 21654541 Paper 21652542 Paper 21613822 Paper 21570461 Paper 21420030 Paper 21258211 Paper 20716952 Paper 19851352 Paper 19508171 Paper 19292977 Paper 19147554 Paper 19047086 Paper 18799194 Paper 18758789 Paper 18719196 Paper 17903452 Paper 17360542 Paper 17135311 Paper 17016645 Paper 16731742 Paper 16596258 Paper 16320109 Paper 15811853 Paper 15249209 Paper 15150118 Paper 12467210 Paper 11555612 Paper 11511564

Abstract

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with an overall 5-year survival rate of 6%. The molecular mechanisms that contribute to the biological aggressiveness of PDAC are being gradually elucidated, and the crucial role of high and low frequency driver mutations in PDAC is providing new insights into the complexity of this cancer. However, the widespread consequences of aberrant transforming growth factor-beta (TGF-beta) actions in PDAC in the context of the presence of oncogenic Kras and loss of function of the retinoblastoma protein are not well understood. In this proposal we will use a novel genetically engineered mouse model (GEM) of PDAC that we generated in which oncogenic Kras is combined with RB deletion. The resultant KRC mice rapidly develop pancreatic intraepithelial (PanIN) lesions that progress to PDAC within weeks after birth, and the pancreatic cancer cells in these cancers are highly proliferative. Based on our published data and preliminary results, the KRC mouse will allow us to test the hypothesis that aberrant TGF-beta signaling in PDAC synergizes with RB inactivation, leading to deleterious actions by TGF-beta, aberrant mitogenic signaling, and enhanced pancreatic cancer cell proliferation and cancer cell-stroma interactions. We will evaluate the effects of RB loss of function on TGF-beta signaling, assess the role of TGF-beta signaling in PDAC metastasis, and delineate the contributions of inflammatory cytokines and Wnt pathways to pancreatic cancer cell proliferation and stroma formation. To this end we will use cell lines established from KRC pancreata, use other novel GEMs of PDAC generated in our laboratory that exhibit a high incidence of metastases, conduct therapeutic interventions in these GEMs, and assess the role of these pathways in human PDAC. The proposed studies will advance our understanding of PDAC pathobiology in a high impact manner, and will point the way to novel therapies for suppressing cancer growth and metastasis.

View original record on NIH RePORTER →